CTOs on the Move

Kyverna Therapeutics

www.kyvernatx.com

 
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases. Our therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of disease. Kyverna is venture-backed and located in the San Francisco East Bay.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Karen Walker
Chief Technology Officer Profile

Funding

Kyverna Therapeutics raised $25M on 01/13/2020

Similar Companies

Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.

Lathrop

Lathrop is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NeuroVista Corporation

NeuroVista Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alltrna

Alltrna is the first transfer RNA (tRNA) platform company, and our mission is to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Alltrna`s platform combines internal expertise and proprietary machine learning tools to unlock the entire tRNA biology space. We have an unprecedented opportunity to advance a single tRNA medicine to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation.

Nerium International

At Nerium International, making people better means establishing a business that can bring real change to your life, your skin, and your personal development.   Through our partnership with Nerium SkinCare, a division of Nerium Biotechnology, Inc., Nerium International markets breakthrough products validated by real science.   These age-defying skincare products are distributed exclusively by our Independent Brand Partners.